Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WSJER
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NV102
|
|||||
| Synonyms |
DoxantiCD19; Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle; NV-102; NV 102
Click to Show/Hide
|
|||||
| Organization |
NanoValent Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
